Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments

Summary

The PROPHETIC study is a prospective, multi-center, international clinical study aimed at developing an algorithm to predict patient outcomes. The study involves analyzing the proteomic profiles of patients undergoing therapy to assess the likelihood of clinical benefit from their prescribed treatment. Blood samples are collected prior to and during the treatment period and analyzed as part of the ongoing development of thealgorithm.

Conditions

• Stage IV Non-small Cell Lung Cancer
• Stage IV Malignant Melanoma
• Stage IV Small Cell Lung Cancer
• Stage III Unresectable Non-Small Cell Lung Cancer
• Stage IIIb-d Malignant Melanoma

Interventions

OTHER

Plasma sample collection

Collect at least two plasma samples

Sponsors & Collaborators

• OncoHost Ltd.

  lead INDUSTRY

Principal Investigators

• Alona Zer, MD · Rambam Health Care Campus

• Michal Lotem, MD · Hadassah Medical Organization

• Jair Bar, MD · Sheba Medical Center

• Maya Gottfried, MD · Meir Medical Center

• Abed Agbaria, MD · Bnai Zion Medical Center

• Ido Wolf, MD · Tel-Aviv Sourasky Medical Center

• Mahmud Abu-Amana, MD · haemek medical center

• Rivka Katsenelson, MD · Kaplan Medical Center

• Alexander Yakobson, MD · Soroka University Medical Center

• Tatiana Harkovsky, MD · Barzilai Medical Center

• Mor Moskovitz, MD · Rabin Medical Center

• Elizabeta Dudnik, MD · Assuta Medical Center

• Raya Leibowitz, MD · Assaf-Harofeh Medical Center

• Adam Berger, MD · Rutgers Cancer Institute

• Jose Lutzky, MD · University of Miami

• Antony Magliocco, MD · Protean BioDiagnostics

• Gillian Price, MD · Aberdeen Royal Infirmary

• Helen Cheley · Swansea Bay UHB - Cancer Institute

• Louise Medley, MD · Torbay and South Devon NHS foundation

• Tom Geldart, MD · Royal Bournemouth General Hospital Dorset

• Anirban Chatterjee, MD · The Shrewsbury and Telford Hospital

• Sean Brown, MD · Gloucestershire Hospitals NHS Foundation Trust

• Andreas Polychronis, MD · Mount Vernon Cancer Centre

• Andreas Polychronis, MD · Lister Hospital

• Ari VanderWalde, MD · West Clinic

• Davika Das, MD · VAHCS Birmingham

• Alison Brewster, MD · Withybush Hospital Hawl Dda University Health Board

• Adam Hassani · Sunderland Royal Hospital

• Adam Hassani, MD · South Tyneside District

• Andrew Conn, MD · Bradford Teaching Hospitals

• Yanyan Lou, MD · Mayo Clinic

• Igor Puzanov, MD · Roswell Park

• Ernesto Bustinza, MD · Florida Cancer Specialists and Research Institute

• Huang Quillan, MD · Michael E. DeBakey VA Medical Center

• Ronnie Shapira Frommer, MD · Sheba Medical Center

• Astrid Ammendola, MD · Asklepios Klinik Gauting GmbH

• Petros Christopoulos, MD · Thoraxklinik-Heidelberg gGmbH

• Marina Messinger, MD · Northwest Community Healthcare

• Sunil Patel, MD · CHRISTUS St. Michael Health System

• Bharat P Jenigiri, MD · Physicians Clinic of Iowa

• David Vecente, MD · Hospital Universitario Virgen Macarena

• Eugenie Younger, MD · Gloucestershire Hospitals NHS Foundation Trust

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-10-01

Primary Completion

2029-10-01

Completion

2029-10-01

Countries

• United States
• Germany
• Israel
• Spain
• United Kingdom

Study Locations